Derivatives of 3h imidazo 4, 5-b pyridine as Selective inhibitors of GSK3 and internediarios, Methods for their preparation, Pharmaceutical compositions containing them and their use for the preparation of a Medicament for the treatment of Neurodegenerative Diseases and mental disorders.

摘要

A process for their Preparation and Intermediates used therein, Pharmaceutical formulations containing Said therapeutically Active compounds and to the use of said compounds in therapy of Mental and Neurodegenerative Diseases.Claim 1: a compound of the formula (1) wherein X is as shown in the compound of formula (2); and R1 is selected from h, halogen, CN, CO2H, NO2, c1-3 alkyl, haloalquilo c1-3, prays, so2nrbrc, nrbrc, C (o) ch2nrbrc, ch2orh, so2ri and C (OR) RJ; R2 and R4 are selected. Nera Independent between h, Halo, CN, NO2, c1-3 alkyl, haloalquilo c1-3, prays, so2nrbrc, nrbrc, C (o)Ch2nrbrc, ch2orh, so2ri and C (OR) RJ; R3 and R5 are independently selected from h, alkyl haloalquilo C1 and C1 - 3 - 3; aryl or heteroaryl is optionally substituted with one or more alkyl CO2H CN, C1, C1 - 6 - 6, haloalquilo, Halo, C (o) ra, Ork, prays, nrbrc C (OR), or s (MRN), where the alqui The C1 - 6 - 6 or haloalquilo C1 is optionally substituted with at least one NS,Prays or nrbrc; and Z is selected from alkyl ch2ord C1, - 6, and ch2z heteroaryl; Z is optionally substituted with one or more alkyl C1 CN, - 6, - 6 haloalquilo C1, Halo, C (or c) ra, ork, nrbrc (OR), or s (MRN), where the alkyl or haloalquilo C1 C1 - 6 - 6 is optionally substituted with at least u CN n, ora or nrbrc; ra is selected from h, alkyl haloalquilo C1 and C1 - 3 - 3Where the c1-3 alkyl or haloalquilo c1-3 is optionally substituted with one or more alkoxy c1-3; RB and RC are independently selected from h, heteroaryl alkyl haloalquilo C1 and C1 - 6 - 6, where the alkyl or haloalquilo C1 C1 - 6 - 6 is optionally substituted with one or more S (ORA or nrdre; or RB and RC can form, together with the Atom to which they are United.A Heterocyclic Ring of 4, 5, 6 or 7 members that contain one or more heteroatoms selected from N, o or s, where the Heterocyclic ring is optionally substituted with one or more Halo, prays, nrdre, c1-3 alkyl or haloalquilo c1-3,Where the c1-3 alkyl or haloalquilo c1-3 is optionally substituted with one or more alkoxy c1-3; Rd and re are independently selected from h, alkyl or haloalquilo C1 C1 - 6 - 6, where the alkyl or haloalquilo C1 C1 - 6 - 6 is optionally substituted with one or more or A; or Rd and re can form, together with the Atom to which they are United, a Heterocyclic Ring 4, 56 or 7 members that contain one or more heteroatoms selected from N, o or s, where the Heterocyclic ring is optionally substituted with one or more Halo, c1-3 alkyl or haloalquilo c1-3 alkyl, wherein the C1 - 3 or haloalquilo c1-3 is optionally substituted by one or more S alkoxy c1-3; RH is HC1-3 alkyl or haloalquilo c1-3 optionally substituted with one or more alkoxy c1-3; RI is haloalquilo c1-3 alkyl or c1-3 alkyl, wherein the C1 - 3 or haloalquilo c1-3 is optionally substituted with one or more ora; RJ is aryl or heteroaryl, aryl or heteroaryl where that is optionally s Ustituido with one or more alkyl c1-3, ora, Halo or CN; rk is alkyl or haloalquilo C1 C1 - 6 - 6Where the alkyl or haloalquilo C1 C1 - 6 - 6 is optionally substituted with at least one CN, prays, nrbrc, C (o) or nrbrc NRBC (or RC); Rm is c1-3 alkyl optionally substituted with at least one Halo, CN, prays, nrbrc (or nrbrc; or (c) n is 0 to 3; in the form of Free Base or a Salt, solvate or solvate The pharmaceutically acceptable Salt thereof.